Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 9/20 | 0.52 |
| ▸ | PARP11 | Q9NR21 | 7/20 | 0.52 |
| ▸ | PARP1 | P09874 | 4/20 | 0.52 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.52 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 3/20 | 0.44 |
| ▸ | GRM5 | P41594 | 2/20 | 0.43 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.42 |
| ▸ | TUBB | P07437 | 1/20 | 0.42 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.42 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.42 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.42 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.42 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.42 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.42 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.42 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.42 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.42 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.42 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15648949 | 0.81 | AURKA (0.54) | PARP1SRD5A1JAK2GRM5 | |
| SCHEMBL19308811 | 0.79 | PARP10 (0.53) | PARP10PARP11PARP1PDPK1TUBB4A | |
| SCHEMBL1613107 | 0.78 | PARP1 (0.54) | PARP10PARP11PARP1PDPK1TUBB4A | |
| SCHEMBL11774277 | 0.78 | PARP1 (0.54) | PARP10PARP11PARP1PDPK1GRM5 | |
| SCHEMBL12714991 | 0.78 | PARP10 (0.54) | PARP10PARP11PARP1PDPK1GRM5 | |
| SCHEMBL21612903 | 0.78 | PARP10 (0.54) | PARP10PARP11PARP1PDPK1TUBB4A | |
| SCHEMBL807894 | 0.76 | PARP10 (0.53) | PARP10PARP11PARP1PDPK1JAK2 | |
| SCHEMBL30459611 | 0.74 | SRD5A1 (0.44) | PARP1SRD5A1JAK2 | |
| SCHEMBL609771 | 0.74 | PARP10 (0.50) | PARP10PARP11PARP1PDPK1JAK2 | |
| SCHEMBL14726020 | 0.74 | PARP10 (0.47) | PARP10PARP11PARP1PDPK1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12331035-B2 | Bicyclic compound and use thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2025-06-17 | — | — | US | disclosed |
| EP-4330246-A1 | HALO-SUBSTITUTED AMINO AZA-HETEROARYL COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | Ontario Institute for Cancer Research (OICR) (CA) | 2024-03-06 | — | — | EP | disclosed |
| CN-117597336-A | Halogen substituted amino aza-heteroaryl compounds as inhibitors of hematopoietic progenitor kinase 1 (HPK 1) | 安大略省癌症研究所(OICR) | 2024-02-23 | — | — | CN | disclosed |
| WO-2023107417-A1 | HETEROCYCLIC ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| US-20230174542-A1 | HETEROCYCLIC ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20230174542-A1 | HETEROCYCLIC ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20230023140-A1 | BICYCLIC COMPOUND AND USE THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2023-01-26 | — | — | US | disclosed |
| WO-2022226665-A1 | HALO-SUBSTITUTED AMINO AZA-HETEROARYL COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-11-03 | — | — | WO | disclosed |
| WO-2022226668-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-11-03 | — | — | WO | disclosed |
| EP-4050006-A1 | BICYCLIC COMPOUND AND USE THEREOF | SK Biopharmaceuticals Co., Ltd. (KR) | 2022-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230023140-A1 | BICYCLIC COMPOUND AND USE THEREOF | PRMT5, PRMT6, PRMT1 | PARP10 58/4885PARP11 63/4885PARP1 205/4885 |
| US-12331035-B2 | Bicyclic compound and use thereof | PRMT5, PRMT6, PRMT1 | PARP10 58/4885PARP11 63/4885PARP1 205/4885 |
| US-20230174542-A1 | HETEROCYCLIC ANTIVIRAL AGENTS | ACE, SARS1, ACE2 | PARP10 1723/4885PARP11 1269/4885PARP1 850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.